When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab

Academic Article

Abstract

  • INTRODUCTION: Colorectal cancer is the third most common cancer in the United States. The use of bevacizumab (Avastin), a vascular endothelial growth factor (VEGF) inhibitor, has been increasing due to observed improvement in metastatic colon cancer survival, but so has the incidence of bowel perforation. We present one unusual complication of bowel perforation, a colovesical fistula in a colorectal cancer patient treated with bevacizumab.
  • Authors

    Published In

    Digital Object Identifier (doi)

    Author List

  • Chen J; Smalligan RD; Nadesan S
  • Start Page

  • 120
  • End Page

  • 122
  • Volume

  • 44
  • Issue

  • 3